Isolated and Associated Effects of Physical Exercise and Estrogen Therapy on Climactercs Women (TRH01/989-7)

This study will investigate the isolated and the associated effect of estrogen therapy and physical exercise in the function, regulation and cardiovascular risk markers of 60 postmenopausal women, (45 - 60 years old). The volunteers will be randomaized into two groups: estrogen therapy (estradiol valerate 1 mg/day oraly) and placebo. The two groups will be randomaized into two subgroups: exercise group (aerobic trainning,cicle-ergometre, 50 minutes, 3 x week) and sedentary group. At 0, 6 and 12 months the volunteers will be submited to: clinical analise, cardiorespiratory analise (ergoepirometric test), quality of life questionare (Short Form-36 [SF-36]), ambulatory blood pressure monitoring during 24 hours and to 2 experimental sessions where the cardiovascular responses to insulin action (euglicemic/hiperinsulinemic clamp) and to physical and mental stress (microneurography) will be accessed. Besides these, the volunteers of the sedentary group will be submited to an extra session at 6 months of study evaluate the physiological answer to insulin infusion after an acute session of exercise.

Study Overview

• Status: Completed
• Conditions: Women's Health
• Intervention / Treatment: Drug: Placebo; Other: Control; Drug: Estradiol valerate; Other: Aerobic training

Detailed Description

More than an isolated event, menopause is an universal process that produces many physiologic changes, affecting not only the reproductive tissues but other systems of women's body. Post-menopause period is usually accompanied by an increase in climacteric symptoms, which decrease healthy related quality of life. Moreover, many unhealthy changes occur at this period of women's life, increasing the risk for metabolic syndrome development, which might be due, at least in part, to an increase in insulin resistance and compensatory hyperinsulinemia.

Hormone therapy is indicated as the main treatment to reduce or relief the negative effects of menopause. Although many studies have confirmed the possible positive effects of this approach on postmenopausal symptoms, its effects on insulin resistance and other metabolic syndrome factors remain controversial.

On the other hand, it's well known that acute and chronic exercises can provide a wide range of benefits for postmenopausal women's health, including decrease of insulin resistance and symptoms relief.

In clinical practice, many postmenopausal women are using hormone therapy and are instructed to exercise. However, the effects of this association are poorly studied.

Thus, the main goal of this randomized placebo-controlled trial was to evaluate, in healthy, middle age, and hysterectomized postmenopausal women, the single and combined effects of physical exercise and oral estrogen use on blood pressure (BP), heart rate (HR), muscle blood flow, and autonomic function measured at baseline conditions and under hyperinsulinemia stimulus. Moreover, it also investigated the effects of these interventions on symptoms relief and quality of life.

• Study Type: Interventional
• Enrollment (Actual): 62
• Phase: Not Applicable

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 45 years to 60 years (Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: Female

Description

Inclusion Criteria:

• Hysterectomy women, with or without ovaries, confirmed by transvaginal ultrasound.
• Climacteric women, postmenopausal for at least 1 year, with vasomotor symptoms (Kupperman, 1959) and/or laboratory diagnosis of menopause (high luteinizing hormone [LH] and follicle-stimulating hormone [FSH] and estradiol decreased).

Exclusion Criteria:

• Hypertension or other cardiovascular disease (thromboembolism, heart disease, myocardial infarction, stroke, vascular disorders, coronary insufficiency or venous)
• Osteoporosis.
• Diagnose or suspected breast cancer or ovaries.
• Current illness or a history of severe liver failure, jaundice or severe pruritus pregnancy and liver tumor.
• Endocrine and metabolic diseases as diabetes, thyroid disorders, obesity and dyslipidemia.
• Chronic diseases such as kidney diseases and collagen diseases.
• Women with cervical or vaginal malignancies.
• Hypersensitivity to estradiol valerate.
• Previous use of estrogen-containing implants in the last two years, use of hormone replacement therapy (HRT) orally or transdermally in the last three months or HRT use by injection in the last six months before the study start.
• Limited mobility or other physical problems that contraindicate the physical exercises.
• Women who are engaged in regular physical activity.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Health Services Research
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: PLACEBO-CONTROL; PLACEBO + CONTROL TO EXERCISE	Drug: Placebo; lactose powder, corn starch, microcrystalline cellulose, and magnesium stearate; Other: Control; The control group was advised to maintain their normal habits, and not to begin any physical exercise program during the study period; Other Names: sedentary
Experimental: ESTROGEN THERAPY + CONTROL; ESTROGEN THERAPY (estradiol valerate 1 mg/dia orally) + CONTROL TO EXERCISE	Other: Control; The control group was advised to maintain their normal habits, and not to begin any physical exercise program during the study period; Other Names: sedentary; Drug: Estradiol valerate; estradiol valerate, 1 mg/day, orally.; Other Names: hormone therapy
Experimental: PLACEBO+AEROBIC TRAINING; PLACEBO + AEROBIC TRAINING (cicle-ergometer, 50 minutes, 3x week)	Drug: Placebo; lactose powder, corn starch, microcrystalline cellulose, and magnesium stearate; Other: Aerobic training; Aerobic trainin (cycleergometer, 3x/week, moderate intensity, 50 minutes); Other Names: physical training
Experimental: ESTROGEN THERAPY + AEROBIC TRAINING; ESTROGEN THERAPY (estradiol valerate 1 mg/dia orally) + AEROBIC TRAINING (cicle-ergometer, 50 minutes, 3x week)	Drug: Estradiol valerate; estradiol valerate, 1 mg/day, orally.; Other Names: hormone therapy; Other: Aerobic training; Aerobic trainin (cycleergometer, 3x/week, moderate intensity, 50 minutes); Other Names: physical training

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Blood pressure	Blood pressure will be measured as often as needed, respecting the interval 1-2 minutes among measurements, until you obtain three consecutive measurements with a difference of less than 5 mmHg by auscultation and oscilometric methods. The verification of calibration of the monitor is often assessed by comparison with the mercury.	six months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
hemodynamics mechanisms	Hemodynamics mechanisms will be evaluate by air-occlusion pletismography	six months
autonomics mechanisms	autonomics mechanisms will be evaluated by microneurography methods and heart rate and blood pressure variability	six months

Collaborators and Investigators

• Sponsor: University of Sao Paulo General Hospital
• Collaborators: Fundação de Amparo à Pesquisa do Estado de São Paulo
• Investigators: Principal Investigator: Angela M Fonseca, PhD, University of Sao Paulo; Principal Investigator: Decio Mion Jr, PhD, University of Sao Paulo; Principal Investigator: Cláudia LM Forjaz, PhD, University of Sao Paulo; Principal Investigator: Sandra B Abrahão, PhD, University of Sao Paulo; Principal Investigator: Taís Tinucci, PhD, University of Sao Paulo

Study record dates

Study Major Dates

• Study Start: February 1, 2002
• Primary Completion (Actual): February 1, 2009
• Study Completion (Actual): February 1, 2009

Study Registration Dates

• First Submitted: April 28, 2010
• First Submitted That Met QC Criteria: May 7, 2010
• First Posted (Estimate): May 11, 2010

Study Record Updates

• Last Update Posted (Estimate): June 22, 2012
• Last Update Submitted That Met QC Criteria: June 21, 2012
• Last Verified: June 1, 2012

More Information

Terms related to this study

• Keywords: exercise; women's health; hormone replacement therapy
• Additional Relevant MeSH Terms: Physiological Effects of Drugs; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Estrogens; Contraceptive Agents, Hormonal; Contraceptive Agents; Reproductive Control Agents; Contraceptive Agents, Female; Estradiol; Estradiol 17 beta-cypionate; Estradiol 3-benzoate; Polyestradiol phosphate
• Other Study ID Numbers: TRH01/989-7